Chart Still Down, But the Earnings Case Was Real — The Day I Bought Samsung Biologics
Today's macro backdrop was neutral, the kind of day that looks uneventful, but I quietly opened a new position. Samsung Biologics. I also closed out the 2 shares of KEPCO I'd been holding, booking a realized -9.4%. With only these two trades on the tape, the story stays clean.
The chart is pinned down, but the earnings engine is real
The case for Samsung Biologics is right there in the scorecard. Overall grade: B, at 59.7 points.
| Factor | Score |
|---|---|
| Fundamentals | 85 |
| Catalyst | 65 |
| Valuation | 58 |
| Risk | 45 |
| Technical | 32 |
Fundamentals at 85 stands out from the other five factors by a wide margin, while Technical sits at just 32 — the textbook picture of a name whose substance is ahead of its chart. Valuation at 58 and Catalyst at 65 hold the middle ground above average, and Risk at 45 stays within a manageable range, so I read that 59.7 not as a signal to force a trade today, but as a cue to claim a spot in the portfolio and watch how it develops.
Closing KEPCO was simpler by comparison. As a rate-sensitive utility, nothing in a neutral macro backdrop gave it a reason to bounce, and I wasn't going to keep holding while the loss hardened, so I sold the 2 shares, booking -9.4% and moved on.
Samsung Electro-Mechanics and Rainbow Robotics stay on the watch list only, again. Neither one's overall score or grade is solid enough yet to justify buying, in my view, and I have no reason to open my wallet until the technical score wakes up or the valuation gets visibly cheap relative to the fundamentals.
Looking at the portfolio now, Samsung Biologics is a bet on earnings power, and closing KEPCO is a call not to let a loss keep dragging. One new position, one cut loss — but the direction is clear: I make room early for names with good numbers even when the chart lags, and I don't let a loss ride just because the macro backdrop reads neutral.